[go: up one dir, main page]

MX2012012421A - Compuestos tetrahidrobenzotiofena. - Google Patents

Compuestos tetrahidrobenzotiofena.

Info

Publication number
MX2012012421A
MX2012012421A MX2012012421A MX2012012421A MX2012012421A MX 2012012421 A MX2012012421 A MX 2012012421A MX 2012012421 A MX2012012421 A MX 2012012421A MX 2012012421 A MX2012012421 A MX 2012012421A MX 2012012421 A MX2012012421 A MX 2012012421A
Authority
MX
Mexico
Prior art keywords
group
lower alkyl
hyperphosphatemia
npt
iib
Prior art date
Application number
MX2012012421A
Other languages
English (en)
Inventor
Hiroyuki Moritomo
Daisuke Kaga
Ippei Sato
Yoh Terada
Yoshimasa Imamura
Masanori Miura
Koji Kato
Shinichiro Hachiya
Kazuhiro Terai
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2012012421A publication Critical patent/MX2012012421A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El propósito es proporcionar un compuesto que tiene una acción inhibitoria del transportador (TNP-llb) fosfato intestinal y es útil como ingrediente activo de un agente para tratar y/o prevenir la hiperfosfatemia. Un compuesto de tetrahidrobenzotiofer io de la siguiente fórmula (I) que tiene una acción inhibitoria del TNP-llb y puede utilizarse como un agente para tratar y/o prevenir la hiperfosfatemia: (Ver Formula). donde, R1 representa -O-alquilo inferior, -alquileno-fenilo inferior, o similares; R2 y R3 son iguales o diferentes entre sí y representan H, alquilo inferior, cicloalquilo, arilo, heteroarilo o similares; o R2 y R3 que pueden combinarse con un átomo de nitrógeno al que se unen para formar un amino cíclico saturado de 5-a 7- miembros; R4's son iguales o diferentes entre sí y representan halógeno, alquilo inferior; y -OH, -O-alquilo inferior, -NO2, o un grupo representado por la fórmula (II):. n representa O a 2.
MX2012012421A 2010-04-28 2011-04-27 Compuestos tetrahidrobenzotiofena. MX2012012421A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010104044 2010-04-28
PCT/JP2011/060261 WO2011136269A1 (ja) 2010-04-28 2011-04-27 テトラヒドロベンゾチオフェン化合物

Publications (1)

Publication Number Publication Date
MX2012012421A true MX2012012421A (es) 2012-12-17

Family

ID=44861567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012421A MX2012012421A (es) 2010-04-28 2011-04-27 Compuestos tetrahidrobenzotiofena.

Country Status (15)

Country Link
US (3) US20130029973A1 (es)
EP (1) EP2565190B1 (es)
JP (1) JP5617919B2 (es)
KR (1) KR101721025B1 (es)
CN (1) CN102869656B (es)
AU (1) AU2011246072B2 (es)
BR (1) BR112012025390B8 (es)
CA (1) CA2793856C (es)
EA (1) EA022521B1 (es)
ES (1) ES2539722T3 (es)
MX (1) MX2012012421A (es)
PH (1) PH12012501851A1 (es)
PL (1) PL2565190T3 (es)
PT (1) PT2565190E (es)
WO (1) WO2011136269A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130029973A1 (en) 2010-04-28 2013-01-31 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
WO2013129435A1 (ja) * 2012-02-28 2013-09-06 協和発酵キリン株式会社 縮環チオフェン誘導体
WO2014003153A1 (ja) * 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
HRP20201211T1 (hr) 2013-03-13 2020-11-13 Chugai Seiyaku Kabushiki Kaisha Derivat dihidropiridazin-3,5-diona
TWI594975B (zh) * 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
WO2016026372A1 (zh) * 2014-08-22 2016-02-25 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用
EP3928779B1 (en) 2014-09-12 2024-03-06 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
ES2864277T3 (es) * 2014-09-26 2021-10-13 Daiichi Sankyo Co Ltd Sal de compuestos de ácido dicarboxílico
CN105524053B (zh) * 2014-10-19 2020-06-05 广东东阳光药业有限公司 四氢苯并噻吩化合物
TW201700458A (zh) * 2015-04-24 2017-01-01 第一三共股份有限公司 二羧酸化合物之製法
PT3497091T (pt) * 2016-08-15 2020-11-30 Lilly Co Eli Derivados de tiofeno condensados úteis como inibidores de napi-iib
WO2020102889A1 (en) * 2018-11-19 2020-05-28 Fouda Ahmed 4,5,6,7-tetrahydro-l-benzothiophene modulators of retinoic acid receptor related (rar) orphan nuclear receptors (rors)
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
KR20240018523A (ko) 2021-06-08 2024-02-13 추가이 세이야쿠 가부시키가이샤 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007131532A (ja) * 2001-09-28 2007-05-31 Kirin Brewery Co Ltd 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
JPWO2003048134A1 (ja) 2001-12-05 2005-04-14 日本たばこ産業株式会社 トリアゾール化合物及びその医薬用途
IL154306A0 (en) 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
EP1614676A4 (en) * 2003-03-27 2009-03-25 Kirin Pharma Kk CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
WO2005023818A2 (en) 2003-09-10 2005-03-17 Gpc Biotech Ag Heterobicyclic compounds as pharmaceutically active agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
WO2006026619A2 (en) 2004-08-30 2006-03-09 Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using rnase h inhibitors
JP2008517061A (ja) 2004-10-20 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 抗腫瘍剤としての化合物及びそれらの使用
GB0514652D0 (en) 2005-07-15 2005-08-24 Syngenta Ltd Pesticidal mixtures
US20110015239A1 (en) 2007-12-14 2011-01-20 The Regents Of The University Of California Inhibitors of calcium-activated chloride channels
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
JP5236748B2 (ja) 2008-01-08 2013-07-17 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療のためのカンナビノイド受容体のリガンドとしてのプロリン類似体
WO2010003533A2 (en) 2008-06-17 2010-01-14 Institut Pasteur Korea Anti-infective compounds
US20130029973A1 (en) 2010-04-28 2013-01-31 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Also Published As

Publication number Publication date
US9284295B2 (en) 2016-03-15
AU2011246072A1 (en) 2012-10-11
KR101721025B1 (ko) 2017-03-29
KR20130073908A (ko) 2013-07-03
BR112012025390A2 (pt) 2016-06-28
US8729068B2 (en) 2014-05-20
BR112012025390B1 (pt) 2021-10-13
AU2011246072B2 (en) 2014-06-26
JP5617919B2 (ja) 2014-11-05
EP2565190B1 (en) 2015-06-03
WO2011136269A1 (ja) 2011-11-03
EA022521B1 (ru) 2016-01-29
PH12012501851A1 (en) 2013-02-04
US20130053369A1 (en) 2013-02-28
ES2539722T3 (es) 2015-07-03
BR112012025390B8 (pt) 2022-11-22
PL2565190T3 (pl) 2015-10-30
JPWO2011136269A1 (ja) 2013-07-22
CN102869656B (zh) 2014-03-12
CN102869656A (zh) 2013-01-09
PT2565190E (pt) 2015-08-24
EA201291121A1 (ru) 2013-04-30
US20140329802A1 (en) 2014-11-06
CA2793856A1 (en) 2011-11-03
EP2565190A1 (en) 2013-03-06
EP2565190A4 (en) 2013-08-21
US20130029973A1 (en) 2013-01-31
CA2793856C (en) 2018-07-17

Similar Documents

Publication Publication Date Title
MX2012012421A (es) Compuestos tetrahidrobenzotiofena.
PH12012501711A1 (en) [5,6] heterocyclic compound
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX2012007060A (es) Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria.
PH12016501822A1 (en) Cyclopropaneamine compound
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
PH12016502037B1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
GEP20146109B (en) Fxr (nr1h4) binding and activity modulating compounds
PH12012502572A1 (en) Novel nicotinamide derivative or salt thereof
MX336381B (es) Boronatos como inhibidores de arginasa.
GEP201706728B (en) Noxious organism control agent
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
GEP201606555B (en) Compounds and compositions for modulating egfr activity
PH12012501546A1 (en) Substituted pyrrolidine-2-carboxamides
MX342377B (es) Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
PH12015502429A1 (en) Dicarboxylic acid compound
IN2014DN07509A (es)
PH12012501552A1 (en) Therapeutic or prophylactic agent for biliary diseases
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MX2009000768A (es) Lactamas macrociclicas.
IN2013MN00506A (es)
SI1970372T1 (sl) Soli 9-oksoakridin-10-ocetne kisline z 1-alkilamino-1-deoksi-polioli
WO2011103524A8 (en) Cyclic tetrapeptides and therapeutic applications thereof
MX2012013589A (es) Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk).

Legal Events

Date Code Title Description
FG Grant or registration